Investment banks Jefferies and Leerink Swann are co-lead underwriters of OncoMed's initial public offering (IPO).

OncoMed Pharmaceuticals, a US-based cancer treatment developer backed by drugs maker GlaxoSmithKline, has filed for a $115m flotation on the Nasdaq stock exchange.

Investment banks Jefferies and Leerink Swann are co-lead underwriters of OncoMed’s initial public offering (IPO).

The company reports a $15m net loss for 2011 on around $30m in revenue.

Shareholders include GlaxoSmithKline (11.74%) and venture capital firms US Venture Partners (17.28% pre-IPO stake), Latterell Venture Partners (12.19%), Vertical Group (11.22%), Morgenthaler Ventures (10.98%), Phase4 Ventures…